Nuklearkardiologie – Aktueller Stand der klinischen Anwendung

Zusammenfassung

Das Positionspapier der Deutschen Gesellschaft für Nuklearmedizin (DGN) und der Deutschen Gesellschaft für Kardiologie (DGK) aktualisiert die gemeinsame Stellungnahme aus dem Jahr 2018. Es gibt einen Überblick über die Einsatzbereiche und den aktuellen Stellenwert der nuklearkardiologischen Bildgebung. Behandelt werden die Themenfelder chronisches Koronarsyndrom einschließlich der Vitalitätsdiagnostik und der besonderen Bedeutung der PET, Kardiomyopathien, kardiale Sarkoidose, Amyloidose, infektiöse Endokarditis und Entzündung kardialer Implantate.

Conclusion for practice

Nuclear cardiology modalities remain a key component in evaluating perfusion and myocardial viability in chronic coronary syndrome, and in the diagnostic evaluation of amyloidosis, sarcoidosis, and endocarditis.

Following the integration of CT coronary angiography into the EBM benefits catalogue, a move towards morphology-based diagnostic strategies is anticipated in patients with a 15–50% pre-test probability of obstructive coronary artery disease. In patients with inconclusive findings, the adjunctive use of functional modalities, such as myocardial SPECT, may guide more precise pre-selection for invasive interventions. Furthermore, myocardial SPECT allows the differential diagnosis of INOCA in cases with unremarkable CT angiography, enabling the identification of this prognostically important condition, particularly in women without epicardial coronary stenoses.

Hinweis des Verlags

Der Verlag bleibt im Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Schlüsselwörter

Chronisches Koronarsyndrom - PET - SPECT - Nuklearmedizin - Endokarderkrankungen

Publikationsverlauf

Eingereicht: 08. Oktober 2025

Angenommen: 27. Oktober 2025

Artikel online veröffentlicht:
16. Januar 2026

• Literatur

• 1 Lindner O, Bauersachs J, Bengel FM. et al. Policy paper nuclear cardiology – update 2018 – Current status of clinical practice. Nuklearmedizin 2018; 57: 146-152
• 2 Lindner O, Bauersachs J, Bengel FM. et al. Positionspapier Nuklearkardiologie – Update 2018. Kardiologe 2018; 12: 303-311
• 3 Bundesarztekammer, Bundesvereinigung K, Fachgesellschaften ADWM Nationale Versorgungs-Leitlinie Chronische KHK (Langfassung), 7. Version 2024. AWMF-Register-Nr.: nvl-004. www.register.awmf.org/assets/guidelines/nvl-004l_S3_Chronische-KHK_2024–09.pdf
• 4 Delgado V, Ajmone MN, de Waha S. et al. ESC Guidelines for the management of endocarditis. Eur Heart J 2023; 44: 3948-4042
• 5 Gotuzzo I, Slart R, Gimelli A. et al. Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey and or sed by the EANM and EACVI. Eur J Nucl Med Mol Imaging 2024; 51: 1809-1815
• 6 Lindner O. (Koordinierender Autor), Nuklearmedizin DGN. S1-Leitlinie Myokard-Perfusions-SPECT(-CT). Registernummer 031–006. 2022. www.awmf.org/service/awmf-aktuell/myokard-perfusionsspect-ct
• 7 Vrints C, Andreotti F, Koskinas KC. et al. ESC Guidelines for the management of chronic coronarysyndromes. Eur Heart J 2024; 45: 3415-3537
• 8 Verberne HJ, Acampa W, Anagnostopoulos C. et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT:2015 revision. Eur J Nucl Med Mol Imaging 2015; 42: 1929-1940
• 9 Maier A, Teunissen AJP, Nauta SA. et al. Uncovering atherosclerotic cardiovascular disease by PET imaging. Nat Rev Cardiol 2024; 21: 632-651
• 10 Lindner O, Schafer W, Rischpler C. et al. Myocardial perfusion SPECT in Germany from 2012 to 2021: insights into development and quality indicators. Eur J Nucl Med Mol Imaging 2023; 50: 1621-1628
• 11 Aribas E, van Lennep RJE, Elias-Smale SE. et al. Prevalence of microvascular angina among patients with stable symptoms in the absence of obstructive coronary artery disease: a systematic review. Cardiovasc Res 2022; 118: 763-771
• 12 Neumann FJ, Sousa-Uwa M, Ahlsson A. et al. (2018) ESC/EACTS Guidelines on myocardial revascularization. Euro Intervention 2019; (14) 1435-1534
• 13 Hachamovitch R, Hayes SW, Friedman JD. et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with noprior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107: 2900-2907
• 14 Panza JA, Chrzanowski L, Bonow RO. Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 78: 1068-1077
• 15 Crean A, Khan SN, Davies LC. et al. Assessment of Myocardial Scar; Comparison Between F-FDG PET, CMR and Tc-Sestamibi. Clin Med Cardiol 2009; 3: 69-76
• 16 Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22: 229-245
• 17 Almeida AG, Carpenter JP, Cameli M. et al. Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 2021; 22: e97-e125
• 18 Lindner O, Hacker M, Burchert W. et al. SPECT and PETmyocardial perfusion imaging in Austria, Germany, and Switzerland results of the first joint survey of 2021. Eur J Nucl Med Mol Imaging 2023; 50: 3602-3608
• 19 McDonagh TA, Metra M, Adamo M. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA)of the ESC. Eur J Heart Fail 2022; 24: 4-131
• 20 Chareonthaitawee P, Beanlands RS, Chen W. et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of (18)F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med 2017; 58: 1341-1353
• 21 Cheng RK, Kittleson MM, Beavers CJ. et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024; 149: e1197-e1216
• 22 Slart R, Glaudemans A, Lancellotti P. et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol 2018; 25: 298-319
• 23 Lee H, Schubert EK, Vidula MK. et al. Potential clinical utility of (68)Ga-DOTATATE PET/CT for detection and response assessment in cardiac sarcoidosis. J Nucl Cardiol 2023; 30: 1075-1087
• 24 Greulich S, Gatidis S, Grani C. et al. Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis. JACC Cardiovasc Imaging 2022; 15: 445-456
• 25 ASNC und EANM Deutsche Gesellschaft fur Nuklearmedizin. Kardiale Amyloidose. Leitfaden fur die Praxis. www.asnc.org/wp-content/uploads/2024/05/19110-ASNC-AND-EANM-Amyloidosis-Practice-Points_LRes19–1.pdf
• 26 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133: 2404-2412
• 27 Rettl R, Duca F, Kronberger C. et al. Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2025; 26: 251-260
• 28 Perugini E, Guidalotti PL, Salvi F. et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076-1084
• 29 Aimo A, Ferrari CYF, Castiglione V. et al. PET and Cardiac Amyloidosis: Which Possible Role?. Heart Fail Clin 2024; 20: e11-e21
• 30 Pizzi MN, Roque A, Fernandez-Hidalgo N. et al. Improving the Diagnosis of Infective Endocarditis in Prosthetic Valves and Intracardiac Devices With 18F-Fluordeoxyglucose Positron Emission Tomography/Computed Tomography Angiography: Initial Results at an Infective Endocarditis Referral Center. Circulation 2015; 132: 1113-1126
• 31 Lindner O. Nuklearmedizinische Bildgebung bei infektioser Endokarditis und Device-Infektionen. Nuklearmediziner 2020; 43: 47-56
• 32 Erba PA, Conti U, Lazzeri E. et al. Added value of 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with infectious endocarditis. J Nucl Med 2012; 53: 1235-1243
• 33 Hyafil F, Rouzet F, Lepage L. et al. Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 586-594
• 34 Rouzet F, Chequer R, Benali K. et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med 2014; 55: 1980-1985
• 35 Juneau D, Golfam M, Hazra S. et al. PositronE mission Tomography and Single-Photon Emission Computed Tomography Imaging in the Diagnosis of Cardiac Implantable Electronic Device Infection: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imaging 2017; 10: e5772
• 36 Bundesamt fur Strahlenschutz. (2021). Bekanntmachung der aktualisierten diagnostischen Referenzwerte fur nukleramedizinische Untersuchungen. Vom 15. Juni 2021. www.bfs.de/SharedDocs/Downloads/BfS/DE/fachinfo/ion/drw-nuklearmedizin.pdf?__blob=publicationFile&v=1